Plus Therapeutics, Inc. (NASDAQ:PSTV) Stock Has Consensus Target Price of $51.75

Plus Therapeutics, Inc. (NASDAQ:PSTV) has been assigned a consensus recommendation of “Hold” from the six brokerages that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $51.75.

Several equities research analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Plus Therapeutics in a report on Friday, July 17th. Ascendiant Capital Markets cut their target price on shares of Plus Therapeutics from $65.00 to $57.00 and set a “buy” rating on the stock in a report on Monday, June 8th.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Plus Therapeutics stock. Citadel Advisors LLC acquired a new stake in Plus Therapeutics, Inc. (NASDAQ:PSTV) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 25,597 shares of the company’s stock, valued at approximately $112,000. Citadel Advisors LLC owned 0.37% of Plus Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 3.28% of the company’s stock.

Plus Therapeutics Stock Performance

Plus Therapeutics stock opened at $1.99 on Tuesday. The company has a market capitalization of $13.70 million, a P/E ratio of -0.87 and a beta of 1.40. Plus Therapeutics has a fifty-two week low of $2.90 and a fifty-two week high of $23.42. The stock has a 50-day simple moving average of $3.11 and a 200-day simple moving average of $4.57.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.43). The firm had revenue of $0.41 million for the quarter, compared to analysts’ expectations of $1.11 million. Plus Therapeutics had a negative return on equity of 198.48% and a negative net margin of 230.24%. As a group, analysts forecast that Plus Therapeutics will post -3.76 earnings per share for the current year.

About Plus Therapeutics

Plus Therapeutics, Inc is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s technology is designed to deliver radioactive agents directly to tumors while limiting exposure to surrounding healthy tissue.

Its lead investigational product is rhenium-186 nanoliposome, also known as 186RNL or RNL. The treatment uses nanoliposomes to encapsulate the radioisotope rhenium-186 and is being evaluated for cancers affecting the central nervous system, including recurrent glioblastoma and leptomeningeal metastases.